High ZEB2 expression is associated with poor outcome in pancreatic cancer, oral squamous carcinoma, breast cancer, ovarian cancer, gastric cancer, colorectal carcinoma and lung cancer [20–33], which is related to its enhancement of proliferation, adhesion and signal transduction and other biological processes. This evidence concerns the gene ZEB2 and breast cancer.